Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
152.36
+4.06 (2.74%)
Aug 12, 2026, 11:52 AM EDT - Market open
Protagonist Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 420.08 | 128.39 | 97.25 | 186.73 | 125.74 | 123.67 |
Short-Term Investments | 362.5 | 438.97 | 321.66 | 154.89 | 111.61 | 203.24 |
Cash & Short-Term Investments | 782.58 | 567.36 | 418.91 | 341.62 | 237.36 | 326.9 |
Cash Growth | 37.18% | 35.44% | 22.63% | 43.93% | -27.39% | 6.90% |
Other Receivables | 16.78 | 0.12 | 165 | 10 | 0.01 | 4.36 |
Total Trade Receivables | 16.78 | 0.12 | 165 | 10 | 0.01 | 4.36 |
Other Current Assets | 7.79 | 10.09 | 7.73 | 3.96 | 5.71 | 9.48 |
Total Current Assets | 807.15 | 577.57 | 591.64 | 355.58 | 243.08 | 340.74 |
Net Property, Plant & Equipment | 10.4 | 11.69 | 12.61 | 2.15 | 4.63 | 6.73 |
Long-Term Investments | 66.88 | 78.64 | 140.25 | - | - | - |
Other Long-Term Assets | 1.12 | 0.29 | 0.23 | 0.23 | 0.23 | 0.23 |
Total Assets | 885.54 | 668.19 | 744.73 | 357.95 | 247.93 | 347.7 |
Accounts Payable | 3.46 | 5.34 | 1.62 | 0.78 | 3.71 | 2.5 |
Accrued Expenses | 21.67 | 28.27 | 23.69 | 19.36 | 24.96 | 37.72 |
Current Portion of Leases | 2.4 | 2.28 | 0.51 | 1.14 | 2.52 | 2.2 |
Unearned Revenue | 9.66 | 9.55 | 18.89 | - | - | 1.6 |
Other Current Liabilities | - | - | 2.69 | - | - | - |
Total Current Liabilities | 37.18 | 45.44 | 47.4 | 21.27 | 31.18 | 44.02 |
Long-Term Leases | 6.82 | 8.04 | 10.36 | - | 1.14 | 3.66 |
Other Long-Term Liabilities | - | - | 11.68 | - | - | - |
Total Long-Term Liabilities | 6.82 | 8.04 | 22.03 | - | 1.14 | 3.66 |
Total Liabilities | 44 | 53.48 | 69.43 | 21.27 | 32.32 | 47.67 |
Common Stock | 0 | 0 | 0 | 0 | 0 | - |
Additional Paid-in Capital | 1,146 | 1,085 | 1,016 | 952.49 | 752.72 | 709.68 |
Accumulated Other Comprehensive Income | -0.83 | 0.64 | -0.08 | -0.11 | -0.36 | -0.3 |
Retained Earnings | -304.04 | -470.67 | -340.52 | -615.71 | -536.76 | -409.36 |
Shareholders' Equity | 841.54 | 614.71 | 675.3 | 336.68 | 215.61 | 300.02 |
Total Liabilities & Equity | 885.54 | 668.19 | 744.73 | 357.95 | 247.93 | 347.7 |
Total Debt | 9.22 | 10.32 | 10.87 | 1.14 | 3.66 | 5.86 |
Net Cash (Debt) | 773.36 | 557.04 | 408.05 | 340.48 | 233.7 | 321.04 |
Net Cash Growth | 38.30% | 36.51% | 19.85% | 45.69% | -27.21% | 7.07% |
Net Cash Per Share | 11.49 | 8.76 | 6.27 | 6.00 | 4.76 | 6.93 |
Book Value | 841.54 | 614.71 | 675.3 | 336.68 | 215.61 | 300.02 |
Book Value Per Share | 12.50 | 9.67 | 10.38 | 5.93 | 4.40 | 6.48 |
Tangible Book Value | 841.54 | 614.71 | 675.3 | 336.68 | 215.61 | 300.02 |
Tangible Book Value Per Share | 12.50 | 9.67 | 10.38 | 5.93 | 4.40 | 6.48 |